Cargando…
Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study
BACKGROUND: Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281099/ https://www.ncbi.nlm.nih.gov/pubmed/22359611 http://dx.doi.org/10.1371/journal.pone.0031639 |
_version_ | 1782223920310517760 |
---|---|
author | van der Tol, Arjan Van Biesen, Wim Van Laecke, Steven Bogaerts, Kris De Lombaert, Koen Warrinnier, Hans Vanholder, Raymond |
author_facet | van der Tol, Arjan Van Biesen, Wim Van Laecke, Steven Bogaerts, Kris De Lombaert, Koen Warrinnier, Hans Vanholder, Raymond |
author_sort | van der Tol, Arjan |
collection | PubMed |
description | BACKGROUND: Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease. METHODOLOGY/PRINCIPAL FINDINGS: We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients. MAU was defined as albuminuria ≥20 mg/l. A propensity score was created to correct for “bias by indication” to receive a statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication. Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34–3.01). The association between statin use and MAU remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82, 95%CI: 1.14–2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00–3.66) and smoking (OR: 1.49, 95%CI: 0.99–2.26) were associated with MAU. CONCLUSIONS: Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses. |
format | Online Article Text |
id | pubmed-3281099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32810992012-02-22 Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study van der Tol, Arjan Van Biesen, Wim Van Laecke, Steven Bogaerts, Kris De Lombaert, Koen Warrinnier, Hans Vanholder, Raymond PLoS One Research Article BACKGROUND: Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease. METHODOLOGY/PRINCIPAL FINDINGS: We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients. MAU was defined as albuminuria ≥20 mg/l. A propensity score was created to correct for “bias by indication” to receive a statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication. Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34–3.01). The association between statin use and MAU remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82, 95%CI: 1.14–2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00–3.66) and smoking (OR: 1.49, 95%CI: 0.99–2.26) were associated with MAU. CONCLUSIONS: Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses. Public Library of Science 2012-02-16 /pmc/articles/PMC3281099/ /pubmed/22359611 http://dx.doi.org/10.1371/journal.pone.0031639 Text en van der Tol et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article van der Tol, Arjan Van Biesen, Wim Van Laecke, Steven Bogaerts, Kris De Lombaert, Koen Warrinnier, Hans Vanholder, Raymond Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title | Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title_full | Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title_fullStr | Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title_full_unstemmed | Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title_short | Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study |
title_sort | statin use and the presence of microalbuminuria. results from the ericabel trial: a non-interventional epidemiological cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281099/ https://www.ncbi.nlm.nih.gov/pubmed/22359611 http://dx.doi.org/10.1371/journal.pone.0031639 |
work_keys_str_mv | AT vandertolarjan statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT vanbiesenwim statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT vanlaeckesteven statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT bogaertskris statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT delombaertkoen statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT warrinnierhans statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT vanholderraymond statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy |